scholarly journals A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians †

2010 ◽  
Vol 19 (15) ◽  
pp. 3089-3101 ◽  
Author(s):  
Fredrick R. Schumacher ◽  
Iona Cheng ◽  
Matthew L. Freedman ◽  
Lorelei Mucci ◽  
Naomi E. Allen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Comprehensive Analysis ◽  
Blood Levels ◽  
Igf I ◽  
Igfbp 3

scholarly journals Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen1

2000 ◽  
Vol 85 (8) ◽  
pp. 2744-2747
Author(s):  
Patrik Finne ◽  
Anssi Auvinen ◽  
Hannu Koistinen ◽  
Wan-Ming Zhang ◽  
Liisa Määttänen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Elevated Serum ◽  
Prostate Cancer Risk ◽  
Factor I ◽  
Igf I ◽  
Igfbp 3

High serum levels of insulin-like growth factor I (IGF-I) and low levels of IGF-binding protein-3 (IGFBP-3) have been shown to correlate with increased prostate cancer risk. To evaluate this, IGF-I, IGFBP-3, and prostate-specific antigen (PSA) were measured in serum from 665 consecutive men (179 with prostate cancer), aged 55–67 yr, with elevated serum prostate-specific antigen (PSA; ≥4 μg/L) in a screening trial. Men in the highest quartile of IGF-I levels had an odds ratio (OR) for prostate cancer of 0.50 [95% confidence interval (CI) 0.26–0.97] when adjusting for serum IGFBP-3. IGFBP-3 itself was not significantly associated with prostate cancer risk (OR, 1.24; 95% CI, 0.68–2.24). Prostate volume was larger in men without than in those with prostate cancer (P < 0.001), and after adjustment for prostate volume, the negative association between serum IGF-I and prostate cancer risk was no longer significant (OR, 0.57; 95% CI, 0.28–1.16). In screen-positive men with elevated serum PSA, serum IGF-I is not a useful diagnostic test for prostate cancer, but it may be associated with benign prostatic hyperplasia and enlargement.

High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort

2004 ◽  
Vol 22 (15) ◽  
pp. 3104-3112 ◽  
Author(s):  
Pär Stattin ◽  
Sabina Rinaldi ◽  
Carine Biessy ◽  
Ulf-Håkan Stenman ◽  
Göran Hallmans ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Bottom Quartile ◽  
Igf I ◽  
Igfbp 3

PurposeInsulin-like growth factor-I (IGF-I) stimulates proliferation and inhibits apoptosis in prostate cancer cells, and IGF-I has been associated with increased prostate cancer risk in some, but not all, epidemiologic studies.Subjects and MethodsWe extended our previous case-control study nested in the Northern Sweden Health and Disease Cohort, a population-based cohort from a region where little prostate specific antigen (PSA) screening is done. Levels of IGF-I and IGF binding protein-3 (IGFBP-3) were measured in prediagnostic blood samples from a total of 281 men who were subsequently diagnosed with prostate cancer after recruitment (median, 5 years after blood collection) and from 560 matched controls.ResultsLogistic regression analyses showed increases in prostate cancer risk with increasing plasma peptide levels, up to an odds ratio (OR) for top versus bottom quartile of IGF-I of 1.67 (95% CI, 1.02 to 2.71; Ptrend= .05), which was attenuated after adjustment for IGFBP-3 to an OR of 1.47 (95% CI, 0.81 to 2.64; Ptrend= .32). For men younger than 59 years at recruitment, OR for top versus bottom quartile of IGF-I was 4.12 (95% CI, 1.01 to 16.70; Ptrend= .002), which was significantly stronger than for men older than 59 years (Pinteraction= .006). For men with advanced cancer, OR for top versus bottom quartile of IGF-I was 2.87 (95% CI, 1.01 to 8.12; Ptrend= .10).ConclusionOur data add further support for IGF-I as an etiologic factor in prostate cancer and indicate that circulating IGF-I levels measured at a comparatively young age may be most strongly associated with prostate cancer risk.

scholarly journals Implications for Prostate Cancer of Insulin-Like Growth Factor-I (IGF-I) Genetic Variation and Circulating IGF-I Levels

2007 ◽  
Vol 92 (12) ◽  
pp. 4820-4826 ◽  
Author(s):  
Mattias Johansson ◽  
James D. McKay ◽  
Fredrik Wiklund ◽  
Sabina Rinaldi ◽  
Martijn Verheus ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Association Studies ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Increased Risk ◽  
Igf I ◽  
Circulating Levels ◽  
I Gene

Abstract Background: Elevated levels of circulating IGF-I have consistently been associated with increased prostate cancer risk. We recently found a haplotype in the 3′ region of the IGF-I gene associated with increased risk of prostate cancer, and we hypothesized that the observed association is mediated by circulating IGF-I. Materials and Methods: We analyzed haplotypes and three haplotype-tagging single nucleotide polymorphisms (htSNPs) in the 3′ region of the IGF-I gene in relation to circulating levels IGF-I in 698 control subjects from the CAncer Prostate in Sweden (CAPS) study and 575 cases and controls from the prospective Northern Sweden Health and Disease Cohort (NSHDC) study. We also performed a meta-analysis of these two and four other association studies on genetic variation in the 3′ region of the IGF-I gene in relation to circulating IGF-I levels. Results: The IGF-I haplotype previously associated with prostate cancer risk, labeled “TCC,” was associated with elevated levels of IGF-I in the CAPS study (P = 0.02), but not in the NSHDC study. In contrast, two of the three IGF-I htSNPs tagging this haplotype, rs6220 and rs7136446, were associated with elevated levels of IGF-I in the NSHDC (P = 0.03 and P = 0.04, respectively), but not in the CAPS study. In the meta-analysis, the TCC haplotype and the rs6220 SNP were associated with elevated levels of circulating IGF-I (P = 0.001 and P < 0.0001, respectively). Conclusions: Genetic variation in the 3′ region of the IGF-I gene seems to influence circulating levels of IGF-I. This observation is consistent with the hypothesis that variation in the IGF-I gene plays a role in prostate cancer susceptibility by influencing circulating levels of IGF-I.

scholarly journals Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study

2019 ◽  
Vol 28 (7) ◽  
pp. 1259-1261
Author(s):  
Anqi Wang ◽  
John R. Barber ◽  
Adrienne Tin ◽  
Angelo M. De Marzo ◽  
Anna Kottgen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Serum Urate ◽  
Atherosclerosis Risk In Communities ◽  
Atherosclerosis Risk ◽  
Aric Study

Abstract A122: Genetic variation in selenoprotein P, selenium levels, and prostate cancer risk and survival

2010 ◽  
Author(s):  
Kathryn L. Penney ◽  
Haojie Li ◽  
Lorelei A. Mucci ◽  
J. Steven Morris ◽  
Howard D. Sesso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Selenoprotein P

scholarly journals IGF-I, insulin and prostate cancer

2009 ◽  
Vol 53 (8) ◽  
pp. 969-975 ◽  
Author(s):  
Giovanna A. Balarini Lima ◽  
Lívia L. Corrêa ◽  
Rafael Gabrich ◽  
Luiz Carlos D. de Miranda ◽  
Mônica R. Gadelha
Keyword(s):  
Prostate Cancer ◽  
Growth Factors ◽  
Cancer Risk ◽  
Cancer Cells ◽  
Growth Regulation ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Adult Men ◽  
Igf I ◽  
High Insulin

Prostate cancer is the second most frequent malignancy diagnosed in adult men. Androgens are considered the primary growth factors for prostate normal and cancer cells. However, other non-androgenic growth factors are involved in the growth regulation of prostate cancer cells. The association between IGF-I and prostate cancer risk is well established. However, there is no evidence that the measurement of IGF-I enhances the specificity of prostate cancer detection beyond that achievable by serum prostate-specific antigen (PSA) levels. Until now, there is no consensus on the possible association between IGFBP-3 and prostate cancer risk. Although not well established, it seems that high insulin levels are particularly associated with risk of aggressive prostatic tumours. This review describes the physiopathological basis, epidemiological evidence, and animal models that support the association of the IGFs family and insulin with prostate cancer. It also describes the potential therapies targeting these growth factors that, in the future, can be used to treat patients with prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document